[Anti-angiogenic therapies: from theory to practice]

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Context:

• Metastatic cancer presents a significant therapeutic challenge despite advances in tumor pathology.
• Angiogenesis inhibition emerged as a promising strategy, leading to the development of anti-VEGF therapies.
• The clinical efficacy and benefit-risk profile of antiangiogenic agents require careful consideration.

Purpose:

• To review the mechanisms of action of antiangiogenic agents.
• To discuss the primary anti-angiogenic drugs currently in use.
• To evaluate the theoretical advantages and practical limitations of anti-angiogenesis therapies in cancer treatment.

Summary:

• Antiangiogenic therapies target tumor blood vessel formation, a critical process in cancer progression.
• Bevacizumab, an anti-VEGF antibody, was initially approved but later had its breast cancer indication revoked by the FDA due to unfavorable benefit-risk.
• Despite initial enthusiasm, clinical studies over the past five years have tempered expectations for antiangiogenic treatments.

Impact:

• This review provides a balanced perspective on the role of antiangiogenesis in cancer therapy.
• It highlights the importance of ongoing research to refine patient selection and treatment protocols.
• Understanding the limitations of these therapies is crucial for developing more effective and safer cancer treatments.